Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 10/20 | 0.54 |
| ▸ | RHEB | Q15382 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650704 | 0.92 | PRSS12 (0.62) | PRSS12RHEBHDAC6CCR2 | |
| SCHEMBL5651532 | 0.88 | KDR (0.43) | PRSS12RHEBKDRHDAC6 | |
| SCHEMBL5651985 | 0.88 | PRSS12 (0.54) | PRSS12RHEBHDAC6PTGDR2CHEK2 | |
| SCHEMBL5652794 | 0.85 | PRSS12 (0.41) | PRSS12RHEBKDRHDAC6 | |
| SCHEMBL5650474 | 0.85 | CNR1 (0.41) | PRSS12RHEBKDRPTGDR2 | |
| SCHEMBL5651534 | 0.84 | HTT (0.52) | PRSS12HDAC6CHEK2 | |
| SCHEMBL5651818 | 0.83 | FOXO1 (0.42) | PRSS12RHEBKDRHDAC6 | |
| SCHEMBL5650995 | 0.83 | PRSS12 (0.47) | PRSS12RHEBKDRHDAC6 | |
| SCHEMBL5653176 | 0.81 | HDAC6 (0.39) | PRSS12HDAC6PTGDR2 | |
| SCHEMBL5652578 | 0.81 | SIRT2 (0.42) | PRSS12RHEBPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | PRSS12 979/4885RHEB 946/4885KDR 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.